Showing 4671-4680 of 7240 results for "".
- Alopecia Areata Breakthrough: Two Studies Suggest JAK inhibitors May Spur Hair Regrowthhttps://practicaldermatology.com/news/alopecia-areata-breakthrough-two-studies-suggest-jak-inhibitors-may-spur-hair-regrowth/2458427/Taken together, two new studies suggest that JAK inhibitors may play a role in treating alopecia areata. Two JAK inhibitors are already approved by the U.S. FDA, XELJANZ® (tofacitinib citrate) for rheumat
- Ditch the Itch: EpiCeram Helps Relieve Eczema Symptomshttps://practicaldermatology.com/news/ditch-the-itch-epiceram-helps-relieve-eczema-symptoms/2458431/A new survey from PuraCap Pharmaceutical sheds light on the emotional and physical effects of eczema, a pervasive condition that affects 31.6 million people in the US. According to the survey, a large number of people are not getting the relief they need
- FDA Bans 19 Ingredients from Hand Soapshttps://practicaldermatology.com/news/fda-no-more-antibacterials-allowed-in-consumer-soaps/2458446/Antibacterial soaps will soon be gone from store shelves, according to a new rule from the US Food and Drug Administration (FDA). This
- 23andMe Data Helps ID BCC Risk Geneshttps://practicaldermatology.com/news/23andme-data-helps-id-bcc-risk-genes/2458459/New research out of 23andMe and Stanford University School of Medicine pinpoints 31 genetic associations for basal cell carcinoma (BCC), 14 of which are all new. Taken together, these associations are estimated to explain almost 11 percent of the genetic risk for BCC, according to t
- Novel Impetigo Drug on the Horizonhttps://practicaldermatology.com/news/new-impetigo-drug-on-the-horizon/2458518/Medimetriks Pharmaceuticals, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ozenoxacin cream, 1%, a novel, non-fluorinated quinolone for the treatment of impetigo. Medimetriks licensed e
- Alopecia Areata May Protect Against Stroke, Heart Attackhttps://practicaldermatology.com/news/alopecia-areata-may-protect-against-stroke-heart-attack/2458522/Unlike other inflammatory dermatologic conditions, alopecia areata does not appear to increase risk for cardiovascular disease, and it may even protect against stroke, new research suggests. Researchers compared 1,377 alopecia areata patients to 4,131 control subjects. They found th
- Galderma's Cetaphil® Launches Limited-edition Product Display Honoring Camp Wonderhttps://practicaldermatology.com/news/galdermas-cetaphil-launches-limited-edition-product-display-honoring-camp-wonder/2458529/Galderma Laboratories is unveiling a limited-edition product display in partnership with the Children's Skin Disease Foundation (CSDF) and Camp Wonder, an initiative of the CSDF. As part of a fi
- Sernivo Spray Hits Pharmacy Shelveshttps://practicaldermatology.com/news/sernivo-spray-hits-pharmacy-shelves/2458544/Sernivo™ Spray for psoriasis is officially available. Dr. Reddy’s Laboratories’ US subsidiary, Promius Pharma, LLC, U.S. Sernivo™ Spray (betamethasone dipropionate) 0.05% was approved by the Food and Drug Administration (F
- Dark Beer? Green Cabbage? The Scoop on St. Patrick's Day's Hidden Beauty Secretshttps://practicaldermatology.com/news/dark-beer-green-cabbage-the-scoop-on-st-patricks-days-hidden-beauty-secrets/2458647/It’s easy to be green on St. Patrick’s day (March 17th), but many skin care companies are now carrying this torch 365 days a year. And going green isn’t the only St. Paddy’s day tradition that promises beauty benefits. Companies such as
- APP® Membership Now Has More Rewards: Three Syneron Candela Platformshttps://practicaldermatology.com/news/app-membership-now-has-more-rewards-three-syneron-candela-platforms/2458655/Syneron Medical Ltd. and Allergan plc are joining forces to offer three of Syneron Candela's body sculpting and skincare platforms to members of Allergan Partner Privileges® (APP®</